Starling Oncology, Inc. (DFPH) stock intrinsic value fair value estimate & owner earnings analysis

The Oncology Institute manages community-based oncology clinics - 65 locations across California, Nevada, Arizona, Oregon and Florida, with the large majority of patients in California. Local physician groups affiliated with the company treat cancer patients under contracts with health insurers, sometimes for a fixed monthly fee per patient (capitation) and sometimes on a fee-for-service basis, along with a specialty pharmacy that dispenses oral cancer medications. Revenue has grown every year since the company went public in November 2021, from about $203 million to about $503 million in 2025. Growth has come at a cost. Heavy stock-based compensation tied to the 2021 transaction, a string of practice acquisitions that were later written down (a $9.9 million goodwill charge in 2022 and a $16.9 million charge in 2023), and the cost of building out a corporate infrastructure meant the company burned cash every year from 2022 through 2025. That began to change in 2025: stock-based compensation fell by more than half, and the company paid down part of a secured loan and had a restrictive cash covenant removed in February 2025. Cash generation has been uneven quarter to quarter, but the first half of 2026 was the strongest six-month stretch on record, with operating cash flow of $9.7 million versus a $15.2 million cash outflow in the same period a year earlier. Because the company has never had a full profitable year, the base, bear and bull cases below are built up from what has actually happened rather than extrapolated from a single strong quarter. The base case assumes the 2025-2026 cost discipline holds: stock-based compensation and capital spending stay near their current low levels relative to revenue, and the existing clinics keep adding patients under their current contracts at a more modest pace than the historical rate, which included acquisitions and new-market entry that are not assumed to repeat. Under this path, the business moves from a small loss in 2026 toward modest, sustained cash generation over the next several years as revenue grows against a largely fixed corporate cost base. Beyond ten years, nothing in the record supports assuming further margin expansion - the industry itself is described in the filings as consolidating among insurers who are pushing for lower reimbursement rates - so later years are held flat rather than grown. This case is worth approximately $3.10 per share today. The bull case assumes the same 2025-2026 improvements continue at the pace already demonstrated rather than decelerating: sustained positive cash flow, continued reduction in dilutive stock compensation, and revenue growth closer to the roughly 35% year-over-year rate reported for the second quarter of 2026. This case reaches sustained profitability sooner and at a higher level, and is worth approximately $6.35 per share today. The bear case reflects the risks that are actually on record: reimbursement pressure from consolidating insurers, a $110 million secured loan facility (with roughly $86 million drawn) provided by a single lender group, a loan covenant that would be breached if the stock were delisted from Nasdaq, and an equity incentive plan that automatically adds new shares equal to 4% of the fully diluted share count each year through 2031. In this case the 2025-2026 improvement stalls, losses continue, and the business keeps needing outside capital to fund itself, which would dilute current shareholders and leave the secured lender ahead of them in any restructuring. In that scenario there is little to nothing left for common shareholders - the case is valued at approximately negative $0.10 per share, reflecting that the equity could be worth close to nothing, or slightly negative, once continued losses and the secured debt are accounted for. Weighing the demonstrated but still-young turnaround against the leverage and reimbursement risk, a margin-of-safety price of about $1.35 per share is used, well below the base-case estimate, to compensate for the uncertainty. Given how recent the improvement is, this is also conditioned on seeing it continue: specifically, at least one more quarterly report confirming that the positive cash flow seen in the first half of 2026 is continuing, rather than a temporary benefit of the debt restructuring and capital raises completed in 2025. What could not be fully reconciled: a portion (roughly 6%) of the 2022 operating cash flow could not be traced to individually identified line items after accounting for the two large, one-time, merger-related fair-value gains that dominate that year's reconciliation; this does not affect the cash flow, compensation or capital spending figures used directly in the valuation, which come straight from the filed statements.